These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 25858975

  • 1. Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysis.
    Piccolo R, Stefanini GG, Franzone A, Spitzer E, Blöchlinger S, Heg D, Jüni P, Windecker S.
    Circ Cardiovasc Interv; 2015 Apr; 8(4):. PubMed ID: 25858975
    [Abstract] [Full Text] [Related]

  • 2. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).
    Taniwaki M, Stefanini GG, Silber S, Richardt G, Vranckx P, Serruys PW, Buszman PE, Kelbaek H, Windecker S, RESOLUTE All-Comers Investigators.
    J Am Coll Cardiol; 2014 Apr 29; 63(16):1617-25. PubMed ID: 24530680
    [Abstract] [Full Text] [Related]

  • 3. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
    Zocca P, Kok MM, Tandjung K, Danse PW, Jessurun GAJ, Hautvast RWM, van Houwelingen KG, Stoel MG, Schramm AR, Tjon Joe Gin RM, de Man FHAF, Hartmann M, Louwerenburg JHW, Linssen GCM, Löwik MM, Doggen CJM, von Birgelen C.
    JACC Cardiovasc Interv; 2018 Mar 12; 11(5):462-469. PubMed ID: 29519378
    [Abstract] [Full Text] [Related]

  • 4. Outcomes with various drug-eluting or bare metal stents in patients with ST-segment-elevation myocardial infarction: a mixed treatment comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized trials.
    Bangalore S, Amoroso N, Fusaro M, Kumar S, Feit F.
    Circ Cardiovasc Interv; 2013 Aug 12; 6(4):378-90. PubMed ID: 23922145
    [Abstract] [Full Text] [Related]

  • 5. Three-year patient-related and stent-related outcomes of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice (from the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries).
    Lee JM, Park KW, Han JK, Yang HM, Kang HJ, Koo BK, Bae JW, Woo SI, Park JS, Jin DK, Jeon DW, Oh SK, Park JS, Kim DI, Hyon MS, Jeon HK, Lim DS, Kim MG, Rha SW, Her SH, Hwang JY, Kim S, Choi YJ, Kang JH, Moon KW, Jang Y, Kim HS.
    Am J Cardiol; 2014 Nov 01; 114(9):1329-38. PubMed ID: 25217457
    [Abstract] [Full Text] [Related]

  • 6. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G, PRODIGY Investigators.
    JACC Cardiovasc Interv; 2014 Jan 01; 7(1):20-8. PubMed ID: 24332420
    [Abstract] [Full Text] [Related]

  • 7. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
    Li XT, Sun H, Zhang DP, Xu L, Ni ZH, Xia K, Liu Y, Chi YH, He JF, Li WM, Wang HS, Wang LF, Yang XC.
    Coron Artery Dis; 2014 Aug 01; 25(5):405-11. PubMed ID: 24584031
    [Abstract] [Full Text] [Related]

  • 8. Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial.
    Iqbal J, Serruys PW, Silber S, Kelbaek H, Richardt G, Morel MA, Negoita M, Buszman PE, Windecker S.
    Circ Cardiovasc Interv; 2015 Jun 01; 8(6):e002230. PubMed ID: 26047993
    [Abstract] [Full Text] [Related]

  • 9. Comparing Stent Thrombosis associated with Zotarolimus Eluting Stents versus Everolimus Eluting Stents at 1 year follow up: a systematic review and meta-analysis of 6 randomized controlled trials.
    Bundhun PK, Yanamala CM, Huang WQ.
    BMC Cardiovasc Disord; 2017 Mar 16; 17(1):84. PubMed ID: 28302055
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of everolimus-eluting stent versus zotarolimus-eluting stent: A meta-analysis of randomized controlled clinical trials and observational studies.
    Gu H, Hua K, Li W, Wang Y, Yang J.
    Int J Cardiol; 2015 Dec 15; 201():552-60. PubMed ID: 26334379
    [Abstract] [Full Text] [Related]

  • 11. Long-term effect of second-generation drug-eluting stents for coronary artery disease, everolimus-eluting versus zotarolimus-eluting stents: a meta-analysis.
    Qi-Hua L, Qi Z, Yu Z, Xiao-Long L, Hai-Gang J, Jian-Feng Y, Yi S.
    Coron Artery Dis; 2015 May 15; 26(3):259-65. PubMed ID: 25715339
    [Abstract] [Full Text] [Related]

  • 12. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J.
    Circulation; 2012 Jun 12; 125(23):2873-91. PubMed ID: 22586281
    [Abstract] [Full Text] [Related]

  • 13. Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J, Richardt G, Valgimigli M, Schulz S, Singh A, Abdel-Wahab M, Tiroch K, Pache J, Hausleiter J, Byrne RA, Ott I, Ibrahim T, Fusaro M, Seyfarth M, Laugwitz KL, Massberg S, Kastrati A, ISAR-LEFT-MAIN 2 Study Investigators.
    J Am Coll Cardiol; 2013 Dec 03; 62(22):2075-82. PubMed ID: 23973699
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of everolimus and zotarolimus-eluting stents versus first-generation drug-eluting stents in patients with diabetes: A meta-analysis of randomized trials.
    Bavishi C, Baber U, Panwar S, Pirrotta S, Dangas GD, Moreno P, Tamis-Holland J, Kini AS, Sharma SK.
    Int J Cardiol; 2017 Mar 01; 230():310-318. PubMed ID: 28062139
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of zotarolimus-eluting stents compared with sirolimus-eluting stents in patients undergoing percutaneous coronary interventions--a meta-analysis of randomized controlled trials.
    Fan J, Du H, Yin Y, Ling Z, Wu J, Xiao P, Zrenner B.
    Int J Cardiol; 2013 Sep 01; 167(5):2126-33. PubMed ID: 22703941
    [Abstract] [Full Text] [Related]

  • 16. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW, Lee JM, Kang SH, Ahn HS, Kang HJ, Koo BK, Rhew JY, Hwang SH, Lee SY, Kang TS, Kwak CH, Hong BK, Yu CW, Seong IW, Ahn T, Lee HC, Lim SW, Kim HS.
    JACC Cardiovasc Interv; 2014 May 01; 7(5):471-81. PubMed ID: 24852802
    [Abstract] [Full Text] [Related]

  • 17. Zotarolimus-eluting Resolute Integrity versus everolimus-eluting Xience Xpedition stents in the management of very long (>30mm) de novo coronary artery stenosis.
    Patra S, Chakraborty RN, Pande A, Banerjee S, Jena M, Mandal PC, De SK, Khan A, Das SS, Ghosh D, Nag R.
    Cardiovasc Revasc Med; 2017 May 01; 18(3):160-164. PubMed ID: 28017259
    [Abstract] [Full Text] [Related]

  • 18. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.
    von Birgelen C, Sen H, Lam MK, Danse PW, Jessurun GA, Hautvast RW, van Houwelingen GK, Schramm AR, Gin RM, Louwerenburg JW, de Man FH, Stoel MG, Löwik MM, Linssen GC, Saïd SA, Nienhuis MB, Verhorst PM, Basalus MW, Doggen CJ, Tandjung K.
    Lancet; 2014 Feb 01; 383(9915):413-23. PubMed ID: 24183564
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries.
    Park KW, Lee JM, Kang SH, Ahn HS, Yang HM, Lee HY, Kang HJ, Koo BK, Cho J, Gwon HC, Lee SY, Chae IH, Youn TJ, Chae JK, Han KR, Yu CW, Kim HS.
    J Am Coll Cardiol; 2013 Feb 05; 61(5):536-44. PubMed ID: 23273394
    [Abstract] [Full Text] [Related]

  • 20. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.
    von Birgelen C, Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG, Louwerenburg JH, Linssen GC, Saïd SA, Kleijne MA, Sen H, Löwik MM, van der Palen J, Verhorst PM, de Man FH.
    J Am Coll Cardiol; 2012 Apr 10; 59(15):1350-61. PubMed ID: 22341737
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.